Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen NASDAQ: AMGN executives used a Jefferies investor conference appearance to emphasize the company's first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide.